Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Obstructive Lung Diseases

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 28 articles:
HTML format
Text format



Single Articles


    September 2018
  1. PAPI A, Singh D, Petruzzelli S, Guasconi A, et al
    Inhaled triple therapy in chronic obstructive pulmonary disease - Authors' reply.
    Lancet. 2018;392:1113-1114.
    PubMed     Text format    


  2. MARCHAND E
    Inhaled triple therapy in chronic obstructive pulmonary disease.
    Lancet. 2018;392:1112.
    PubMed     Text format    


  3. LIPWORTH B, Kuo CR, Jabbal S
    Inhaled triple therapy in chronic obstructive pulmonary disease.
    Lancet. 2018;392:1112-1113.
    PubMed     Text format    


  4. MOLIMARD M, Girodet PO, Moore N
    Inhaled triple therapy in chronic obstructive pulmonary disease.
    Lancet. 2018;392:1112.
    PubMed     Text format    


  5. VALENZUELA PL, Santos-Lozano A, Morales JS, Drobnic F, et al
    Free to breathe hard in the Tour de France.
    Lancet. 2018;392:1114-1115.
    PubMed     Text format    


  6. ZAR HJ, Nicol MP
    Treatment of bronchiectasis exacerbations in children: which antibiotic?
    Lancet. 2018 Sep 17. pii: S0140-6736(18)32004.
    PubMed     Text format    


  7. GOYAL V, Grimwood K, Byrnes CA, Morris PS, et al
    Amoxicillin-clavulanate versus azithromycin for respiratory exacerbations in children with bronchiectasis (BEST-2): a multicentre, double-blind, non-inferiority, randomised controlled trial.
    Lancet. 2018 Sep 17. pii: S0140-6736(18)31723.
    PubMed     Text format     Abstract available


  8. FLUME PA, Chalmers JD, Olivier KN
    Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity.
    Lancet. 2018;392:880-890.
    PubMed     Text format     Abstract available


  9. CHANG AB, Bush A, Grimwood K
    Bronchiectasis in children: diagnosis and treatment.
    Lancet. 2018;392:866-879.
    PubMed     Text format     Abstract available


    April 2018
  10. VESTBO J, Mathioudakis AG
    The emerging Chinese COPD epidemic.
    Lancet. 2018;391:1642-1643.
    PubMed     Text format    


  11. WANG C, Xu J, Yang L, Xu Y, et al
    Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study.
    Lancet. 2018;391:1706-1717.
    PubMed     Text format     Abstract available


  12. THE LANCET
    UK COPD treatment: failing to progress.
    Lancet. 2018;391:1550.
    PubMed     Text format    


    March 2018
  13. AGUSTI A
    Filling the gaps in COPD: the TRIBUTE study.
    Lancet. 2018;391:1004-1006.
    PubMed     Text format    


  14. PAPI A, Vestbo J, Fabbri L, Corradi M, et al
    Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial.
    Lancet. 2018;391:1076-1084.
    PubMed     Text format     Abstract available


    February 2018
  15. THE LANCET
    Asthma in US children.
    Lancet. 2018;391:632.
    PubMed     Text format    


    January 2018
  16. MOSLER G, Euba T
    Taking control through drama.
    Lancet. 2018;391:303-304.
    PubMed     Text format    


  17. WATTS G
    Ian Pavord: engaging with the eosinophil.
    Lancet. 2018;391:301.
    PubMed     Text format    


  18. CROOKS MG, Faruqi S, Morice AH
    How does azithromycin improve asthma exacerbations?
    Lancet. 2018;391:28.
    PubMed     Text format    


  19. GIBSON PG
    How does azithromycin improve asthma exacerbations? - Author's reply.
    Lancet. 2018;391:28-29.
    PubMed     Text format    


    December 2017
  20. PAPI A, Brightling C, Pedersen SE, Reddel HK, et al
    Asthma.
    Lancet. 2017 Dec 19. pii: S0140-6736(17)33311.
    PubMed     Text format     Abstract available


  21. SINHARAY R, Gong J, Barratt B, Ohman-Strickland P, et al
    Respiratory and cardiovascular responses to walking down a traffic-polluted road compared with walking in a traffic-free area in participants aged 60 years and older with chronic lung or heart disease and age-matched healthy controls: a randomised, cr
    Lancet. 2017 Dec 5. pii: S0140-6736(17)32643.
    PubMed     Text format     Abstract available


    September 2017
  22. DAVIES P, Bradley C
    Vanishing lung syndrome: giant bullous emphysema.
    Lancet. 2017 Sep 28. pii: S0140-6736(17)32246.
    PubMed     Text format    


  23. PAVORD ID, Beasley R, Agusti A, Anderson GP, et al
    After asthma: redefining airways diseases.
    Lancet. 2017 Sep 11. pii: S0140-6736(17)30879.
    PubMed     Text format    


  24. KLEINERT S, Horton R
    After asthma: airways diseases need a new name and a revolution.
    Lancet. 2017 Sep 11. pii: S0140-6736(17)32205.
    PubMed     Text format    


  25. CAMARGO CA JR
    Transformational thinking about asthma.
    Lancet. 2017 Sep 11. pii: S0140-6736(17)32126.
    PubMed     Text format    


  26. WOODCOCK A, Vestbo J, Bakerly ND, New J, et al
    Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial.
    Lancet. 2017 Sep 8. pii: S0140-6736(17)32397.
    PubMed     Text format     Abstract available


  27. GIBSON P
    Effectiveness trials in asthma: time to SaLSA?
    Lancet. 2017 Sep 8. pii: S0140-6736(17)32398.
    PubMed     Text format    


    February 2017
  28. THE LANCET
    Complexities of care in COPD.
    Lancet. 2017;389:574.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Obstructive Lung Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: